-+ 0.00%
-+ 0.00%
-+ 0.00%

Press Release: SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Dow Jones·03/31/2026 10:40:00

Please log in to view news